^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    3d
    BLESSING—Ⅰ: An open-label, single-arm Phase I clinical study of SENL103 autologous T-cell injection (S103) for the treatment of refractory generalized myasthenia gravis (ChiCTR2500112137)
    P1, N=18, Not yet recruiting, Tangdu Hospital, the Fourth Military Medical University; Tangdu Hospital, the Fourth Military Medical University
    New P1 trial
    14d
    CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Tongji Hospital
    New P1 trial • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • SDC1 (Syndecan 1) • IL13 (Interleukin 13) • IL4 (Interleukin 4)
    |
    AZD0120
    17d
    Intra-procedure white blood cell monitoring as a predictor of collection efficiency in mononuclear cell apheresis. (PubMed, Transfus Apher Sci)
    Intra-procedure WBC concentration correlates with collection efficiency and provides a more meaningful real-time indicator of MNC harvest performance than pre-procedure counts alone. Incorporating intra-procedure monitoring into apheresis workflows may enhance yield predictability and streamline CAR-T manufacturing logistics.
    Journal
    |
    CD34 (CD34 molecule)
    |
    Carvykti (ciltacabtagene autoleucel)
    18d
    CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. (PubMed, Nat Med)
    Among 198 patients treated with ciltacabtagene autoleucel or idecabtagene vicleucel (June 2021-December 2024), 27 (13.6%) developed CirAEs. CirAEs were associated with significantly higher non-relapse mortality (hazard ratio = 5.2, P = 0.006), and independent risk factors included ciltacabtagene autoleucel (odds ratio = 4.5, P = 0.058), peak absolute lymphocyte count ≥ 2.4 × 103 per microliter in the first 14 days post-infusion (odds ratio = 4.3, P  1 (odds ratio = 2.6, P = 0.048). We identified marked CD4+ CAR T cell infiltration in all available CirAE tissues, including cerebrospinal fluid during neurologic CirAEs, implicating CD4+ CAR T cell therapy as a key mediator of these toxicities.
    Journal • Adverse events
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Abecma (idecabtagene vicleucel) • Carvykti (ciltacabtagene autoleucel)
    19d
    A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Huashan Hospital
    New P1 trial
    21d
    Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=60, Recruiting, Hadassah Medical Organization
    New P1 trial
    24d
    Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Cartesian Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Descartes-08
    25d
    BCMA-CD19 cCAR T for the Treatment of Refractory Lupus (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, iCell Gene Therapeutics
    New P1/2 trial
    |
    cyclophosphamide
    26d
    IASO206 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial
    29d
    Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=31, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Carvykti (ciltacabtagene autoleucel) • Talvey (talquetamab-tgvs)
    1m
    CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=12, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial
    1m
    Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial